Major Depressive Disorder (MDD) Statistics in US 2026 | MDD Facts

Major Depressive Disorder in America 2026

Major depressive disorder is not sadness. That distinction matters, and getting it right is the starting point for understanding the true scale of what the data reveals. Sadness is a normal human emotion with an identifiable cause — a loss, a disappointment, a difficult season — that resolves with time. Major depressive disorder (MDD) is a clinically defined illness characterized by persistent depressed mood or loss of interest in previously enjoyed activities for at least two weeks, accompanied by a constellation of symptoms including disrupted sleep, appetite changes, fatigue, difficulty concentrating, feelings of worthlessness, and in its most severe form, recurrent thoughts of death or suicidal ideation. Under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), MDD is a distinct, diagnosable psychiatric condition — and in the United States in 2026, the data makes clear it is one of the most widespread and costly diseases in the nation. According to the National Institute of Mental Health (NIMH), citing the 2021 National Survey on Drug Use and Health (NSDUH), an estimated 21.0 million US adults aged 18 or older — representing 8.3% of all US adults — had at least one major depressive episode (MDE) in the past year. Among adolescents aged 12 to 17, the most recent data from SAMHSA’s 2024 NSDUH — released July 28, 2025 — found that 15.4% (3.8 million) had a past-year MDE, a meaningful decline from the pandemic-era peak of 20.8% in 2021. And the CDC’s own NCHS Data Brief No. 527, published in April 2025 — the most recent federal government depression prevalence report — confirmed via NHANES data collected August 2021 through August 2023 that 13.1% of all Americans aged 12 and older had depression in any given two-week period, up sharply from 8.2% in 2013–2014, a near-doubling of prevalence in a decade.

These numbers represent the federal government’s clearest and most current picture of the MDD crisis in America — and the picture is deeply concerning. What makes the data even more troubling is what it reveals about treatment. The NIMH’s statistics on adult MDE show that approximately 39% of adults with major depressive episodes did not receive any treatment, and only 39.3% of Americans aged 12 and older with depression received counseling or therapy in the past 12 months, according to CDC/NCHS Data Brief No. 527 (April 2025). The economic consequences of this undertreated disease are immense. The most comprehensive peer-reviewed study of MDD’s economic burden in the US — Greenberg et al., published in Advances in Therapy in October 2023 — calculated that the total incremental societal economic burden of MDD was $333.7 billion in 2019, equivalent to $382.4 billion in 2023 USD, driven primarily by healthcare costs ($127.3 billion), household disruption costs ($80.1 billion), and workplace presenteeism ($43.3 billion). MDD is not a personal struggle happening quietly behind closed doors. It is a national public health and economic emergency touching tens of millions of American lives across every age group, income level, race, and geography — and the 2026 data makes that clearer than ever.

Interesting Facts About Major Depressive Disorder (MDD) in the US 2026

Sources: NIMH, “Major Depression,” citing SAMHSA 2021 NSDUH, last updated July 2023; SAMHSA, 2024 National Survey on Drug Use and Health (NSDUH), released July 28, 2025; CDC/NCHS Data Brief No. 527, “Depression Prevalence in Adolescents and Adults: United States, August 2021–August 2023,” Brody and Hughes, April 2025;

The statistics in the table above represent a convergence of multiple independent federal data systems — all pointing in the same direction. The near-60% increase in depression prevalence over a single decade, documented by the CDC/NCHS using the gold-standard NHANES survey instrument and the clinically validated PHQ-9 depression screener, is not a methodological artifact. It reflects a genuine and accelerating deterioration in American mental health that spans both adolescents and adults, both sexes, and all income levels. The 10.3% adult female MDE prevalence versus 6.2% for adult males — a gap of more than four percentage points — has been consistent across multiple NSDUH cycles and reflects both real differences in biological vulnerability and systematic differences in symptom recognition and diagnosis. And the fact that 87.9% of Americans with depression report that it makes their work, home, or social activities more difficult — while only 39.3% receive professional counseling or therapy — defines the core paradox of MDD in the United States: a disease so common and so disabling that it affects nearly every American family, yet one whose treatment gap remains chronically, stubbornly wide.

MDD Prevalence by Age in the US in 2026

Sources: CDC/NCHS Data Brief No. 527, “Depression Prevalence in Adolescents and Adults: United States, August 2021–August 2023,” Brody and Hughes, published April 2025 (all NHANES PHQ-9 data); NIMH, “Major Depression Statistics,” citing SAMHSA 2021 NSDUH (adult MDE prevalence by age); SAMHSA, 2024 National Survey on Drug Use and Health, released July 28, 2025 (adolescent MDE figures).

The age pattern revealed by CDC’s April 2025 NHANES data is one of the most important structural findings in American mental health epidemiology. Depression prevalence follows a clear inverse relationship with age: adolescents aged 12–19 carry the highest depression burden at 19.2%, declining through each successive age group to a low of 8.7% among adults aged 60 and older. But that declining prevalence with age does not mean older adults are protected — it means they are less likely to be captured by symptom-based screening instruments that weight tearfulness, low mood, and anhedonia more heavily than the somatic symptoms — pain, fatigue, sleep disruption — that more commonly characterize depression in older adults. The 19.0% depression prevalence among women aged 20–39 is among the most striking single statistics in the entire NHANES dataset: it means that nearly 1 in 5 young American women is clinically depressed in any given two-week period. For adolescent girls specifically, the 26.5% prevalence — more than double the 12.2% rate among adolescent boys — documents a genuine gender-specific mental health emergency in the 12–19 age range that has persisted and widened over the past decade.

The adolescent trend data from SAMHSA’s 2024 NSDUH is one of the few genuinely encouraging signals in the otherwise grim US MDD data landscape. Adolescent MDE fell from a pandemic-era high of 20.8% in 2021 to 15.4% in 2024 — a 5.4 percentage-point decline across three years. Serious adolescent suicidal ideation also declined from 12.9% in 2021 to 10.1% in 2024, and suicide plan-making fell from 6.2% to 4.6%. SAMHSA’s July 2025 release explicitly acknowledged “declines in a number of adolescent mental health measures between 2021 and 2024, including major depressive episode with and without severe impairment.” This improvement likely reflects multiple overlapping factors: the post-pandemic restoration of school-based social environments, expanded telehealth access for mental health care, and the impact of increased public attention and awareness on early help-seeking. The improvement should not, however, obscure the baseline: a 15.4% adolescent MDE prevalence — affecting 3.8 million American teenagers — remains far above any pre-2016 historical benchmark, and 2.8 million of those adolescents have MDE with severe impairment.

MDD Prevalence by Sex in the US in 2026

Sources: NIMH, “Major Depression Statistics,” citing SAMHSA 2021 NSDUH — adult MDE by sex; CDC/NCHS Data Brief No. 527, April 2025 — all NHANES PHQ-9 age-by-sex prevalence data and counseling receipt data; SAMHSA, 2024 NSDUH, July 28, 2025.

The female-to-male gap in depression is one of the most replicated findings in psychiatric epidemiology, and the 2025 and 2026 federal data confirm it with precision. Among adults, NIMH reports a gap of 10.3% versus 6.2% — female versus male past-year MDE, representing a 4.1 percentage-point difference and a roughly 66% higher relative prevalence in women. The NHANES-based NCHS Data Brief No. 527 shows an even wider gap at the population level: 16.0% of females versus 10.1% of males aged 12 and older, a 5.9 percentage-point absolute difference. The biological mechanisms behind this gap are well-established and include the modulatory effects of female sex hormones on serotonin and other monoamine systems — particularly the vulnerability periods associated with menstrual cycling, the postpartum period, and the perimenopausal transition — as well as higher rates of adverse childhood experiences in females, including sexual abuse and trauma, which are among the strongest environmental predictors of MDD onset. Social factors including economic inequality, caregiving burdens, and interpersonal violence exposure also contribute to sustained elevated MDD risk in women.

The treatment gap between men and women is critically important and often discussed in reverse of its actual direction. The data from NCHS Data Brief No. 527 shows that 43.0% of women with depression received counseling or therapy in the past 12 months, compared to only 33.2% of men — a nearly 10 percentage-point treatment gap that disadvantages men. While women have higher absolute rates of MDD, men with depression are significantly less likely to access professional treatment. This male treatment gap reflects deeply ingrained cultural norms around masculinity and self-reliance, different symptom expression patterns — depressed men are more likely to present with irritability, anger, and risk-taking behavior rather than tearfulness or expressed hopelessness — and clinician bias in recognizing and diagnosing MDD in male patients. The combination of higher MDD-related mortality (through suicide, where men predominate) with lower treatment rates makes the male depression treatment gap a serious and underappreciated public health problem within an already underserved population.

MDD Prevalence by Income in the US in 2026

Sources: CDC/NCHS Data Brief No. 527, “Depression Prevalence in Adolescents and Adults: United States, August 2021–August 2023,” Brody and Hughes, April 2025, Tables 2 and full income-by-sex breakdown; Gallup 2025 national survey on depression diagnosis, reported in published analyses current as of early 2026.

The income-depression relationship documented in NCHS Data Brief No. 527 is stark, consistent, and policy-relevant. Adults and adolescents living below the federal poverty line have a 22.1% depression prevalence — nearly three times the 7.4% rate among those at or above 400% of FPL. Among low-income women specifically, the figure reaches 26.0% — more than one in four. This gradient is not explained by differences in how depression is measured or reported at different income levels; it reflects genuinely higher MDD burden driven by poverty-related stressors: food insecurity, housing instability, elevated exposure to violence and adverse life events, limited access to preventive care and mental health services, and the psychological toll of chronic financial precarity. The NCHS data shows a significant decreasing linear trend in depression prevalence with increasing income level in both females and males — the relationship is dose-dependent and statistically robust. The Gallup 2025 survey data, which captures self-reported current depression or active treatment, documents an even sharper gradient: 35.1% of adults in the lowest income bracket currently have depression, up from 22.1% in 2017 — a 13 percentage-point surge in just eight years among the most economically vulnerable Americans.

What the income data reveals is that depression in America does not affect all citizens equally. The probability that an American has MDD is in large part predictable from their household income — a finding with profound policy implications. For every dollar of income gain that moves a household above the poverty line, the expected reduction in depression risk is measurable and significant. Mental health interventions targeted exclusively at the clinical level — therapy, medication — without addressing the underlying economic determinants of depression will achieve limited lasting impact. The CDC’s April 2025 data brief underscores this explicitly, noting that depression prevalence differences by income “may reflect a number of factors including socioeconomic stressors, differential access to mental health care, and the impact of depression itself on economic productivity” — a bidirectional relationship that creates self-reinforcing cycles of poverty and mental illness that medication and therapy alone cannot fully disrupt.

MDD 10-Year Trend Data in the US in 2026

Sources: CDC/NCHS Data Brief No. 527, “Depression Prevalence in Adolescents and Adults: United States, August 2021–August 2023,” Brody and Hughes, April 2025 — full Figure 3 and Table 3 trend data; SAMHSA 2024 NSDUH released July 28, 2025 — adolescent MDE trend; NIMH Major Depression statistics pages.

The 10-year trend data from CDC/NCHS Data Brief No. 527 published in April 2025 represents the most comprehensive longitudinal picture of depression change in the United States available to date — and it documents a genuine epidemic acceleration. Overall depression prevalence among Americans aged 12 and older rose from 8.2% in 2013–14 to 13.1% in 2021–23, a 4.9 percentage-point absolute increase representing a nearly 60% relative increase over a decade. The NCHS data brief explicitly confirmed “increasing quadratic trend” in females and “increasing linear trend” in males across the entire measurement period — meaning the rise in depression was statistically significant, consistent, and not attributable to measurement noise or methodological change. What is particularly notable in the trend data is that the rise in male depression was proportionally larger: male depression prevalence went from 5.4% to 10.1% — an 87% relative increase — compared to a 46.8% relative increase in female depression. While women maintain higher absolute rates, men are catching up faster, and the reasons deserve more attention than they currently receive in public mental health discourse.

The divergence between adult trends (worsening) and adolescent trends (improving) since 2021 is one of the more nuanced and important findings in current US mental health data. SAMHSA’s July 2025 NSDUH release documented a meaningful improvement in adolescent MDE from 20.8% to 15.4% between 2021 and 2024 — a 5.4 percentage-point decline that represents genuine progress. But adult depression has not shown the same improvement. The NHANES trend data up to August 2023 shows no inflection point in adult prevalence; the most recent adult data point remains 13.1%, the highest recorded level. This bifurcation likely reflects the distinct drivers of adolescent versus adult depression: the adolescent peak was driven heavily by the unique social and educational disruptions of the COVID-19 pandemic, which partially resolved as schools reopened and social environments normalized; adult depression — rooted in economic stress, chronic health conditions, housing costs, and social isolation — has not been similarly addressed by post-pandemic recovery.

MDD Treatment Gap Statistics in the US in 2026

Sources: NIMH “Major Depression Statistics” page, citing SAMHSA 2021 NSDUH; CDC/NCHS Data Brief No. 527, Brody and Hughes, April 2025; SAMHSA 2024 NSDUH, released July 28, 2025; SAMHSA/BHB reporting on treatment barriers, August 2025; NAMI “Mental Health By the Numbers,” updated December 2025.

The MDD treatment gap in the United States — the chasm between how many people have the disease and how many actually receive evidence-based care — is one of the defining failures of the American healthcare system in the 21st century. The NIMH’s data shows that roughly 39% of adults with a past-year major depressive episode received no treatment whatsoever, and the CDC/NCHS April 2025 data reveals that even among those who do receive some form of care, only 39.3% receive counseling or therapy — the treatment modality with the strongest evidence base for MDD, particularly in combination with medication. Men are notably undertreated relative to women: only 33.2% of males with depression accessed counseling or therapy in the past 12 months versus 43.0% of females. SAMHSA’s July 2025 NSDUH release documented that the top reason both adults and adolescents give for not seeking mental health treatment is believing they can handle their depression on their own — cited by 90.5% of untreated adolescents in 2024, a figure that rose 5.2 percentage points in a single year. Among adults, cost concerns rose to become the second-most-cited barrier, displacing “not being ready to start treatment” — a shift that underscores the role of financial barriers in preventing MDD care access. Particularly troubling was a separate SAMHSA finding from July 2025: in 2024, there were 3 million fewer adults and 300,000 fewer adolescents who received any mental health treatment compared to 2023, a significant decline in access at a time when depression prevalence remains historically elevated.

The ~11-year average delay between MDD symptom onset and first treatment — a figure derived from multiple clinical studies and widely cited in the psychiatric literature — is perhaps the single most consequential statistic in understanding why MDD causes such pervasive damage to American lives. MDD that goes untreated for a decade is MDD that disrupts education, derails careers, dissolves relationships, and compounds into co-occurring anxiety disorders, substance use disorders, and cardiovascular disease. The $382.4 billion annual economic burden of MDD documented in the peer-reviewed literature (Greenberg et al., Advances in Therapy, 2023) is in large part the cost of this delay — the accumulated damage of a treatable disease that sits unacknowledged and untreated for years before most affected Americans receive care. The depressive disorders ranking as the #2 cause of inpatient hospitalizations among Americans under 18 (after excluding pregnancy and birth-related causes) — as reported by NAMI citing updated federal data — reflects the downstream consequence of that treatment gap hitting its most acute and crisis-driven endpoint: emergency psychiatric admission.

MDD Economic Burden Statistics in the US in 2026

Sources: Greenberg P et al., “The Economic Burden of Adults with Major Depressive Disorder in the United States (2019),” Advances in Therapy, October 2023, DOI: 10.1007/s12325-023-02622-x (PMC10499687); Greenberg P et al., “The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018),” Pharmacoeconomics, 2021, DOI: 10.1007/s40273-021-01019-4 (PMC8097130); NAMI “Mental Health By the Numbers,” reviewed and updated December 2025; APA, “The Economic Cost of Depression is Increasing,” 2021.

The $382.4 billion annual societal cost of MDD in the United States in 2023 equivalent dollars — drawn from the most methodologically comprehensive economic burden study of MDD published to date — is a number that demands to be understood in context. It is larger than the entire annual gross domestic product of many developed nations. It exceeds the annual federal budget for Medicaid. It represents approximately $1,143 for every single American, whether they have depression or not. The cost structure of MDD is also critically important: the $127.3 billion in direct healthcare costs (38.1% of total) is by far the largest single component, but it is driven primarily not by the cost of treating MDD itself, but by the cost of treating the comorbid conditions that MDD causes or exacerbates — cardiovascular disease, diabetes, obesity, substance use disorders, and chronic pain conditions. The peer-reviewed literature has consistently found that for every dollar spent on direct MDD treatment costs, an additional $2.30 is spent on MDD-related indirect costs (APA, 2021), underscoring how the disease’s economic footprint extends far beyond the psychiatrist’s office.

The demographic shift in MDD’s economic burden is among the most concerning trends in the 2018 data: young adults aged 18–34 accounted for approximately 48% of all adults with depression in 2018, up from just 35% in 2010. This shift toward younger affected workers means that MDD is increasingly disrupting the most economically productive years of Americans’ working lives — the prime earning and career-building years of the third and fourth decades. Workplace costs grew by 73.2% between 2010 and 2018 — the largest growth of any cost component — which directly reflects this shift toward younger, more employed individuals with depression. The women’s 52.6% share of the total economic burden, despite women comprising slightly less than half of the MDD-affected population (62.7% female prevalence × smaller working-age share than men), reflects both the direct costs of healthcare-seeking (women access care at higher rates than men) and the substantial household disruption costs ($80.1 billion) that fall disproportionately on women. The economic case for investing in MDD prevention, early identification, and effective treatment is, in purely financial terms, overwhelming — and the data makes it clearer with every new study.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.